Globus Medical, a spinal surgery medical device developer, raised $100 million in its IPO, essentially half of what it previously filed to raise. The offering included 8.3 million shares priced at $12 apiece, the low end of its updated expected range of $12 to $13. Previously, Globus planned to raise about $200 million by offering 11.8 million shares priced between $16 and $18. Despite the $100 million drop, Globus fared well in its first day of trading on the NYSE under the symbol GMED, with shares rising up to close at $13.50. Clarus Ventures sold nearly 670,000 shares through the offering and now holds an 8.2% stake in Globus, while Goldman Sachs sold no shares and currently holds an 8.5% stake.